<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471818</url>
  </required_header>
  <id_info>
    <org_study_id>(019/024/CPI) /CEI/1332/18)</org_study_id>
    <nct_id>NCT04471818</nct_id>
  </id_info>
  <brief_title>Ketamine or Placebo in Patients With Major Depression and Advanced Cancer</brief_title>
  <acronym>KODIAC</acronym>
  <official_title>Ketamine Versus Placebo as Adjuvant Treatment for Major Depressive Disorder and Wish to Hasten Death in Advanced Cancer Patients Undergoing Palliative Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depression (MD) is a psychiatric disorder characterized by a persistent feeling of
      sadness, anhedonia or a decreased perception of pleasurable experiences, as well as appetite
      alterations and weight variations, sleep disorders, altered psychomotor skills, fatigue,
      guilt, decreased self-worth, suicidal thoughts and difficulty concentrating in a task (1).

      MD is a frequent complication in patients who are diagnosed with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">February 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 19, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Edinburg Depression Scale (BEDS) score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Scale to assess depression validated in cancer patients. For the BEDS scale, 6 items are included and scored, maximum score is 18 and minimum score is 0. Patients screened for depression are considered cases when scoring ≥7 in this scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18 to 65 years of age

          2. Sex: Male or female

          3. Major depressive disorder (MDD) diagnosis as per Diagnostic and Statistical Manual of
             Mental Disorders (DSM-5).

          4. Palliative stage cancer diagnosis (advanced-disease stage)

          5. Who can read and write in spanish

          6. Eastern Cooperative Oncology Group (ECOG) 0-2

          7. Karnofsky ≥ 50

          8. Palliative prognostic index A

          9. Not currently undergoing systemic oncologic treatment

         10. Patients who agree to participate in the study by signing an informed consent.

        Exclusion Criteria:

          1. Comorbidities including other psychiatric diseases (additional to MDD, generalized
             anxiety or panic disorder).

          2. Magnetic resonance or computerized tomography with major structural alterations.

          3. Pregnant or breastfeeding women.

          4. Patients with hypersensitivity to ketamine

          5. Cardiac insufficiency

          6. Patients with a history of psychosis

          7. Patients with first-degree relatives with a history of psychosis

          8. Patients with uncontrolled glaucoma

          9. Current neurological illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oscar Rodríguez, MD</last_name>
    <phone>55 5628 0400</phone>
    <email>oscroma@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología (INCan)</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Rodríguez Mayoral, MD</last_name>
      <phone>55 5628 0400</phone>
      <email>oscroma@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancerologia de Mexico</investigator_affiliation>
    <investigator_full_name>Oscar Raúl Rodríguez Mayoral</investigator_full_name>
    <investigator_title>Head psychiatrist at the Palliative Care Unit of the National Cancer Institute (INCan, Mexico)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

